Lynk Pharmaceuticals Completes Phase III AS Trial Enrollment
HANGZHOU, China, SHANGHAI & BOSTON — July 14, 2026 Lynk Pharmaceuticals Co., Ltd. has announced the successful completion of...
Lynk Pharmaceuticals
Advertisement
Formation Bio Doses First Participant in Phase 1 Trial of BLKR201, a CNS-Penetrant TYK2 Inhibitor
NEW YORK, June 9, 2026 Formation Bio announced the first participant has been dosed in a Phase 1 first-in-human...
Advertisement
